jcm-logo

Journal Browser

Journal Browser

Current Trends and Future Challenges in Percutaneous Coronary Intervention

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiovascular Medicine".

Deadline for manuscript submissions: 20 February 2026 | Viewed by 379

Special Issue Editor


E-Mail Website
Guest Editor
Minneapolis Heart Institute, Minneapolis, MN, USA
Interests: complex coronary PCI; PCI; bifurcation; bifurcation PCI; chronic total occlusion; CTO; mechanical circulatory support; data science

Special Issue Information

Dear Colleagues,

The field of percutaneous coronary intervention (PCI) continues to evolve rapidly, driven by advances in imaging technologies, device innovations, and procedural techniques. Contemporary PCI strategies now offer enhanced precision in lesion assessment and stent deployment, significantly improving patient outcomes. Developments such as intravascular imaging (IVUS, OCT), physiology-guided PCI, and the use of drug-coated balloons are expanding the boundaries of what is achievable in coronary intervention.

Additionally, the treatment of complex coronary lesions—such as chronic total occlusions, bifurcation lesions, and left main disease—has become increasingly feasible, supported by dedicated tools and techniques. The integration of artificial intelligence and robotic-assisted PCI is also beginning to shape the future landscape of interventional cardiology.

Despite these advances, several challenges remain. These include addressing long-term outcomes in high-risk populations, optimizing antithrombotic therapy to balance ischemic and bleeding risks, and improving access to PCI in resource-limited settings. Moreover, the clinical integration of novel technologies and techniques must be guided by robust evidence to ensure safety and efficacy.

In this Special Issue, we invite authors to contribute original research and review articles on the latest clinical advances in PCI, focusing on innovations, unresolved questions, and future directions in the diagnosis and interventional treatment of coronary artery disease.

Dr. Deniz Mutlu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PCI
  • IVUS
  • OCT
  • FFR
  • physiology
  • CT-guided PCI
  • complex PCI
  • CTO
  • bifurcation
  • coronary complications
  • mechanical circulatory support

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 487 KB  
Article
The Impact of Cangrelor in the UK for the Treatment of STEMI Patients with Gastric Absorption Issues Undergoing Percutaneous Coronary Intervention
by Bhavik Modi, Rob Cain, Richard Stork, Gina Tarpey, Alessia Colucciello, Danielle Olivier, Caroline Barwood, Will Wright and Rory McAtamney
J. Clin. Med. 2025, 14(21), 7564; https://doi.org/10.3390/jcm14217564 - 25 Oct 2025
Viewed by 210
Abstract
Background/Objectives: Patients that undergo percutaneous coronary intervention (PCI) require effective antiplatelet therapies to minimize the risk of thrombotic cardiovascular events. Oral P2Y12 inhibitors are often utilized, however co-administered opioids may lead to gastric absorption issues in these patients, affecting the efficacy of [...] Read more.
Background/Objectives: Patients that undergo percutaneous coronary intervention (PCI) require effective antiplatelet therapies to minimize the risk of thrombotic cardiovascular events. Oral P2Y12 inhibitors are often utilized, however co-administered opioids may lead to gastric absorption issues in these patients, affecting the efficacy of oral inhibitors. Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor that could be explored as a potential treatment option for patients with gastric absorption issues during ST-elevation myocardial infarction. The objective was to estimate the UK budget impact of introducing cangrelor for ST-elevation myocardial infarction (STEMI) patients with gastric absorption issues undergoing PCI. Methods: A budget impact model was developed to calculate the impact of introducing cangrelor to treat STEMI patients with gastric absorption issues undergoing PCI, to the UK National Health Service and personal social services, over 5 years. Oral P2Y12 inhibitors (clopidogrel, prasugrel, and ticagrelor), glycoprotein IIb/IIIa inhibitors (eptifibatide and tirofiban), and aspirin and heparin alone were included as base case comparators. Cangrelor uptake ranged from 10% to 30% in years 1–5. The cangrelor-eligible population was estimated at 10,903 patients per year. Results: Over 5 years, cangrelor leads to a small cost saving (0.29%), varying from −GBP 261,989 in year 1 to GBP 174,778 in year 5. The introduction of cangrelor is estimated to lead to 314 fewer hospital days and 190 clinical events avoided over 5 years. Conclusions: Introducing cangrelor to STEMI patients with gastric absorption issues undergoing PCI in the UK is estimated to generate a small cost saving and reduced length of stay for some patients. Full article
Show Figures

Figure 1

Back to TopTop